November 10, 2022
Via: PharmaphorumThe merger will create a clinical-stage cancer-focused biotech with funding that will last into 2024 and pipeline headed by ATX-101, a peptide-targeting PCNA being developed by APIM in clinical trials for platinum-sensitive ovarian cancer and sarcoma. Nordic Nanovector was hit […]
July 19, 2024
July 11, 2024
July 11, 2024